Abiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart Center Hamburg
DANVERS, Mass., April 05, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart recovery and support technologies, announced today that the Impella 5.5(TM) heart pump received CE marking1 approval in Europe and the first patient was treated at University Heart Center in Hamburg, Germany. The Impella 5.5 heart pump further enhances Abiomed's product portfolio and provides physicians a 30-day, ambulatory, wean-able, forward flow heart pump.
Under the leadership of Professor Hermann Reichenspurner, MD, PhD, Alexander Bernhardt, MD treated the first patient, who presented with ischemic cardiomyopathy, severe mitral regurgitation and an ejection fraction of 18%. The patient currently remains stable on Impella 5.5 support.
The Impella 5.5 heart pump has the ability to provide peak flows of greater than 6.0 liters per minute. It is designed to be implanted in the axillary artery, avoiding the need for a sternotomy and allowing for patient ambulation. The Impella 5.5 is approved in Europe for up to 30 days of support and can be adjusted to nine power levels that regulate flow to optimize weaning protocols. The Impella 5.5 device includes the new SmartAssist technology with optical sensor, which will enable the integration of clinical data informatics including Left Ventricular Pressure (LVP), End-Diastolic Pressure (EDP) and Cardiac Power Output (CPO) on the Impella console as well as real-time, exact positioning of the Impella device. Over the next fiscal year, Abiomed plans to launch the Impella 5.5 heart pump through a controlled roll-out at German hospitals with established heart recovery protocols. Abiomed will continue to collect data on Impella 5.5 user experience and patient outcomes through our German hospitals submitting clinical data in the global cVAD Registry study.
Data Supporting CE Marking Approval
The data submitted for this CE marking approval included pre-clinical data on the Impella 5.5 and incorporates the clinical experience from over 3,000 patients, most all with axillary implants treated with the Impella 5.0 device. The submission also included an analysis of 68 patients from Abiomed's FDA reviewed cVAD Registry study treated with Impella 5.0® or Impella LD® heart pumps and a literature review of eight papers identifying patients treated with the Impella 5.0. Additionally, Abiomed submitted an analysis of 17 patients enrolled in the RECOVER I prospective, multicenter FDA IDE study.
"The Impella 5.5 device is an easy to implant, minimally-invasive device that provides full cardiac flow and stabilizes the patient by increasing cardiac power output, unloading the left ventricle and perfusing the coronaries and end organs," said Hermann Reichenspurner, MD, PhD, Professor and Chief, Department of Cardiovascular Surgery, University Heart Center Hamburg. "This approval gives our cardiovascular community a new option for effectively treating severely ill patients."
"We are excited about the Impella 5.5 and the impact of fully unloading the left ventricle," said Michael R. Minogue, President, Chairman and Chief Executive Officer of Abiomed. "We commend the dedication of the team at University Heart Center Hamburg. The addition of the Impella 5.5 to the Impella platform of devices will further address the clinical needs of patients and physicians as we advance the field of heart recovery."
- The CE marking approval for Impella 5.5 intended use is:
The Impella 5.5 heart pump is an intracardiac pump for supporting the left ventricle. It is intended for clinical use in cardiology and in cardiac surgery for up to 30 days for the following indications, as well as others: The Impella 5.5 is a cardiovascular support system for patients with reduced left ventricular function, e.g., post-cardiotomy, low output syndrome, cardiogenic shock after acute myocardial infarction; The Impella 5.5 may also be used as a cardiovascular support system during coronary bypass surgery on the beating heart, particularly in patients with limited preoperative ejection fraction with a high risk of postoperative low output syndrome.
ABOUT IMPELLA HEART PUMPS
The Impella 5.5 heart pump is not approved for use or sale in the United States.
The Impella 2.5®, Impella CP®, Impella CP® with SmartAssist, Impella 5.0® and Impella LD® are FDA-approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP® device, is FDA approved to treat patients experiencing acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries.
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.
This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.
**For further information please contact:
Ingrid Goldberg Ward
Director, Investor Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
HotDocs Wins Prestigious Queen's Award for Enterprise for International Trade26.4.2018 09:01 | Pressmeddelande
EDINBURGH, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- HotDocs, the global leader in document automation software powered by AbacusNext, has been named a winner of the 2018 Queen's Awards for Enterprise, the UK's highest accolade for business success. HotDocs received the award for achievement in International Trade in recognition of thriving overseas growth, accounting for an over seventy percent increase in revenue in the last three years. Since 1965, the Queen's Awards have recognised exceptional UK businesses who excel at international trade, innovations, or sustainable development-they are the highest official UK awards for enterprise excellence. HotDocs will be attending a reception at Buckingham Palace where Prince Charles will present the award on behalf of Her Majesty the Queen. This is HotDoc's second Queen's Award for Enterprise, the first was in 2013, also for excellence in International Trade. "We are proud to have been named a Queen's Award winner for the second ti
Historic GSA Meeting Forges Path for Blockchain Technology in Gaming Industry26.4.2018 09:00 | Pressmeddelande
LONDON, April 26, 2018 (GLOBE NEWSWIRE) -- The Gaming Standards Association's (GSA) recently formed Blockchain Technical Committee held its first meeting in London recently, charting a course to integrate the breakthrough technology into the gaming industry, with the potential to modernize lotteries and online and land-based gaming. The meeting was hosted by Playtech and attending were representatives from member companies, AxesNetwork, ComTrade Gaming, Gaming Laboratories International, Mercury Gaming Gauselmann, IGT, and Scientific Games. The topics of discussion included responsible gaming, machine certification, and jurisdictional licensing. "The spirit of collaboration among the members of this committee was groundbreaking, as everyone understands the mission critical responsibilities for the future of the global gaming industry," said Blockchain Committee Chair Earle G. Hall. "The enthusiasm and understanding of the task of the committee were infectious, and by the end of the day
SmartCash Highlights 2018 Initiatives to Accelerate Global Adoption, Recaps Key Achievements26.4.2018 09:00 | Pressmeddelande
Roadmap milestones focus on further scalability, merchant adoption, security and support NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- SmartCash, a community governance, cooperation and growth focused crypto-asset created via blockchain technology, today provides an overview of its recent achievements and ambitions for the year ahead. Self-funded, Merchant-Centric, Community-Driven and Easy to Use Recent accomplishments have positioned SmartCash to become the ideal choice for making payments anywhere in the world by introducing the following: Username-based addresses vs. highly complex addresses of Bitcoin and other cryptocurrencies Self-funded model to ensure continual development and outreach Transaction fees of less than 1/10th a cent Advanced governance system to give every SmartCash holder a voice SmartNodes to enable InstantPay and other future services Easy-to-use web wallet and mobile app To learn more about SmartCash's innovations, visit https://smartcash.cc/
Medibio Announces Scientific Advisory Board26.4.2018 06:00 | Pressmeddelande
Led by Board of Director Franklyn Prendergast, M.D., Ph.D. and Chief Medical Officer Archie Defillo, M.D. Key external members include Martin Chapman, M.D.; Joel Ehrenkranz, M.D.; Mark A. Frye, M.D.; Lawrence Hunter, Ph.D.; Wallace Mendelson, M.D.; Marie Casey Olseth, M.D., and Giampaolo Perna, M.D., Ph.D. SYDNEY, Australia and MINNEAPOLIS, April 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company confirms establishment of its Scientific Advisory Board (SAB). Scientific Advisory Board Charter/Purpose The Medibio Scientific Advisory Board is charged to advise the board of directors and executive leadership team on scientific matters involving the Company's discovery and development of programs, including major internal projects, interactions with academic and other outside research organizations, and the acquisition of technologies. The SAB will assist directors and management to stay abreast of industry and menta
Madison Realty Capital Provides $35 Million Mezzanine Loan for 611 West 56th Street Condominium Development in Hell's Kitchen26.4.2018 00:51 | Pressmeddelande
Part of Overall $155 Million Financing Package Provided by MRC and Apollo Global Management for Planned 35 Story Condo Tower at 56th Street and Eleventh Avenue First New York City Project Designed by Renowned Architect Álvaro Siza NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Madison Realty Capital (MRC) provided a $35 million mezzanine loan to co-developers Sumaida + Khurana and LENY for a new condominium tower located at 611 West 56th Street in the Hell's Kitchen neighborhood of Manhattan. The funding is part of a $155 million construction financing package for the project provided by MRC and an investment fund managed by Apollo Global Management. Located in the evolving Hudson West neighborhood, 611 West 56th Street will stand 35 stories in height, encompass 163,329 square feet and feature 83 residences, ranging from one-bedrooms to expansive penthouses. The condominium will also feature a significant amount of outdoor space, including a landscaped roof garden and sun deck, as well a
Crocus Technology Raises $35M in Financing26.4.2018 00:36 | Pressmeddelande
Final round of financing to fuel Crocus' rapidly growing TMR magnetic sensor business SANTA CLARA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Crocus Technology, a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces it has secured $35M in funding through a combination of debt and equity from internal investors and external sources. The funding will enable Crocus Technology to accelerate its revenue growth by expanding its operations and go-to-market resources and by investing in the continuous development of innovative products to serve the demand of existing and emerging markets. Crocus' proprietary MLU(TM) technology enables its TMR sensor products to have high magnetic sensitivity with minimal variation over a wide temperature range, coupled with ultra-low power consumption, which makes them ideal sensing solutions for IoT, mobile, automotive, medical and industrial applications. Crocus' TMR integrated sensor products are embedded within a CMOS pro
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum